Skip to search formSkip to main contentSkip to account menu

CMFVP protocol

Known as: Cyclophosphamide/Fluorouracil/Methotrexate/Prednisone/Vincristine, CVFMP protocol, VPCMF 
A combination of agents containing cyclophosphamide, fluorouracil, methotrexate, prednisone and vincristine.
National Institutes of Health

Related topics

Related topics

7 relations

Broader (4)

Antineoplastic Combined Chemotherapy ProtocolsCyclophosphamideMethotrexatecisplatin/cyclophosphamide/etoposide protocol
FluorouracilPrednisoneVincristine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
Proportional hazards and recursive partitioning and amalgamation analyses of the southwest oncology group node-positive adjuvant CMFVP breast cancer data base: a pilot study
SummarySeveral putative prognostic factors have been identified in node-positive breast cancer patients, but their importance… 
Highly Cited
1998
Highly Cited
1998
Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy.
PURPOSE To determine the significance of plasma c-erbB-2 levels to assess the extent of disease spread and to predict the… 
1993
1993
One versus 2 years of CMFVP adjuvant chemotherapy in axillary node-positive and estrogen receptor-negative patients: a Southwest Oncology Group study.
PURPOSE To determine if prolonged adjuvant treatment (2 years v 1 year) with combination chemotherapy (cyclophosphamide… 
1993
1993
An intensive sequenced adjuvant chemotherapy regimen for breast cancer.
Twenty-two women (17 pre- and 5 postmenopausal) with nodepositive, stage II breast carcinoma were treated with adjuvant… 
1989
1989
Combination of Cyclophosphamide, Adriamycin and Platinum (Cap) versus 5-Fluorouracil, Adriamycin and Cyclophosphamide (Fac) as Primary Treatment in Metastatic Breast Cancer: Results of a Prospective…
Based on favorable results we reported earlier with the CAP regimen in breast cancer (CAP vs CMFVP), the present study compared… 
1986
1986
Adjuvant therapy of breast cancer: Southwest Oncology Group studies.
The Southwest Oncology Group has conducted a series of randomized studies of adjuvant therapy in patients with primary breast… 
1985
1985
A randomized trial of CMF versus CMFVP as adjuvant chemotherapy in women with node-positive stage II breast cancer: A CALGB study
Women treated by mastectomy for node-positive breast carcinoma were randomly assigned to receive an induction course and 2 years… 
1985
1985
Cyclophosphamide, Adriamycin and Platinum (CAP) Combination Chemotherapy, A New Effective Approach in the Treatment of Disseminated Breast Cancer. Preliminary Report
The prospective controlled Phase III clinical trial tested the therapeutic value of the cis-platinum-adriamycin-cyclophosphamide… 
1984
1984
Adjuvant systemic therapy in postoperative node-positive patients with breast carcinoma: the CALGB trial and the ECOG premenopausal trial.
  • C. Tormey
  • Recent results in cancer research. Fortschritte…
  • 1984
  • Corpus ID: 28746605
The initial results of the comparison of no systemic treatment to l-phenylalanine mustard (l-PAM) and cyclophosphamide… 
1983
1983
A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancer
SummaryThe Southeastern Cancer Study Group, in a prospectively randomized study involving patients with advanced breast cancer… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)